Biohaven Ltd. Files 8-K with Office and Name Change Details

TL;DR

Biohaven Ltd. updated its 8-K with office address and former name details.

AI Summary

Biohaven Ltd. filed an 8-K on August 15, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing indicates the company's principal executive offices are located at 215 Church Street, New Haven, Connecticut, 06510. Biohaven Ltd. was formerly known as Biohaven Research Ltd. until a name change on June 29, 2022.

Why It Matters

This filing provides an update on Biohaven Ltd.'s corporate information, including its current address and former company name, which is important for investors tracking the company's official status.

Risk Assessment

Risk Level: low — The filing is routine and primarily concerns corporate administrative details rather than significant financial or operational changes.

Key Players & Entities

• Biohaven Ltd. (company) — Registrant
• August 15, 2025 (date) — Date of Report
• 215 Church Street, New Haven, Connecticut, 06510 (address) — Principal executive offices
• Biohaven Research Ltd. (company) — Former company name
• June 29, 2022 (date) — Date of name change

FAQ

Key Financial Figures

• $562.5 m — ales-based milestones, which were up to $562.5 million, and reducing the developmental a
• $575 m — regulatory milestones, which were up to $575 million, to up to $210 million based on r
• $210 million — which were up to $575 million, to up to $210 million based on regulatory approvals in the Un
• $25 million — the Middle East and Asia for BHV-7000 ($25 million of which has already been paid) and up
• $60 million — eady been paid) and up to an additional $60 million based on regulatory approval in the Uni

Filing Documents

• bhvn-20250815.htm (8-K) — 25KB
• exhibit51maplesopinionandc.htm (EX-5.1) — 33KB
• image_0a.jpg (GRAPHIC) — 82KB
• 0001935979-25-000074.txt ( ) — 286KB
• bhvn-20250815.xsd (EX-101.SCH) — 2KB
• bhvn-20250815_def.xml (EX-101.DEF) — 3KB
• bhvn-20250815_lab.xml (EX-101.LAB) — 23KB
• bhvn-20250815_pre.xml (EX-101.PRE) — 14KB
• bhvn-20250815_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On August 15, 2025, Biohaven Ltd. (the "Company") filed a prospectus supplement to its Registration Statement on Form S-3 (No. 333-274822) (the "Registration Statement") filed with the U.S. Securities and Exchange Commission (the "Commission"), under the Securities Act of 1933, as amended, with respect to the resale by the selling shareholder named therein of 3,588,688 common shares, no par value, of the Company that were issued by the Company to such selling shareholder as share consideration in connection with the Amendment to Membership Interest Purchase Agreement , dated as of May 1, 2024 (the "Knopp Amendment"), by and among the Company, Biohaven Therapeutics Ltd., Biohaven Pharmaceuticals, Inc. and the selling shareholder. Under the Knopp Amendment, the parties thereto agreed to replace the scaled high single digit to low teens royalty payment obligations under the Membership Interest Purchase Agreement, dated February 24, 2022 (the "Purchase Agreement"), among Biohaven Therapeutics LTD., Knopp Biosciences LLC, Channel Biosciences, LLC and Biohaven Pharmaceutical Holding Company Ltd., with a flat royalty payment in the mid-single digits for BHV-7000 and the pipeline programs. The parties also agreed to reduce the success-based payments payable under the Purchase Agreement by removing all commercial sales-based milestones, which were up to $562.5 million, and reducing the developmental and regulatory milestones, which were up to $575 million, to up to $210 million based on regulatory approvals in the United States, Europe, the Middle East and Asia for BHV-7000 ($25 million of which has already been paid) and up to an additional $60 million based on regulatory approval in the United States for the other Kv7 pipeline programs. The Company retains the ability to pay these contingent milestone payments in cash or in its common shares at its election. In connection with the filing of the prospectus supplement, the Company is filing a le

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 5.1 Opinion of Maples & Calder. 23.1 Consent of Maples & Calder (included in Exhibit 5.1) . 104 The cover page of this Current Report on Form 8-K formatted as Inline XBRL. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 15, 2025 Biohaven Ltd. By: /s/ Matthew Buten Matthew Buten Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR